TOG Review (RCOG Journal)
MRCOG Part 2
Maternal Medicine
Management of adnexal masses in pregnancy
Key Statistics
- 0.19–8.8% — Prevalence of adnexal mass in pregnancy
- 1:1500–32,000 — Incidence of ovarian malignancy
- 76% — Are simple cysts <5 CM
Don't-miss facts
-
Do not operate before 14–16 weeks unless acute — removing the corpus luteum may cause miscarriage
-
Surgery indicated: acute abdomen · suspicious mass · growth >20% · cyst >10 cm (labour obstruction)
-
Torsion: 1–5/10,000 pregnancies, 16% with OHSS — operate immediately; presence of ovarian Doppler flow does not exclude it
-
CA125 raised by decidua (peak 1st trimester); suggested cut-off 112 U/ml at 11–14 weeks. LDH unaffected by pregnancy
-
Any IOTA M rule → refer to gynaecological oncology MDT (IOTA sensitivity 95%, specificity 91%)
-
Dermoid >6 cm: torsion risk ~27%; dermoids are the commonest cystic lesion after 16 weeks
-
Laparoscopy safe at 12–15 mmHg; use Hasson/Palmer’s entry; laparotomy if malignancy suspected (port-site metastases, spillage)
-
Doxycycline contraindicated >15 weeks for PID; OHSS — do not drain, operate only for torsion/rupture
Ultrasound buzzwords
Ring of fire – corpus luteal cyst Spoke wheel – hyperstimulated ovaries White ball (hair/sebum) – dermoid
Ground glass – endometrioma Beads-on-a-string – hydrosalpinx Whirlpool sign – torsion
Crescent sign – excludes invasive cancer, not LMP
Malignant ultrasound features
Solid components Papillary projections >6 mm High colour score in projections Growth >20% between scans
Septations Free fluid beyond pouch of Douglas
Abbreviation Key
- LMP — low malignant potential (borderline)
- LDH — lactate dehydrogenase
- OHSS — ovarian hyperstimulation syndrome
- hCG — human chorionic gonadotrophin
- IOTA — International Ovarian Tumour Analysis
- MDT — multidisciplinary team
- RMI — risk of malignancy index
- FNA — fine needle aspiration
- ROMA — Risk of Ovarian Malignancy Algorithm
- FIGO — International Federation of Gynecology and Obstetrics
- HE4 — human epididymis protein 4
- PID — pelvic inflammatory disease
Source: Alalade AO, Maraj H. Management of adnexal masses in pregnancy. The Obstetrician & Gynaecologist 2017;19:317–325. doi:10.1111/tog.12417
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).